Discovery of novel N-(prop-2-yn-1-yl)-1,2,3,4-tetrahydronaphthalen-1-amine derivatives as MAO-B inhibitors for the treatment of Parkinson’s disease
Original: https://doi.org/10.1080/14756366.2025.2606434 Monoamine oxidase B (MAO-B) inhibitors are commonly used to treat Parkinson’s disease, because they help increase dopamine levels in the brain. In this study, researchers designed and made a new group of chemical compounds and tested them to see how well they block the human MAO-B enzyme. Main findings How they work Further … Read more